Equities

Nextgen Biomed Ltd

NXGN:TLV

Nextgen Biomed Ltd

Actions
TechnologyTechnology
  • Price (ILa)101.80
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-69.70%
  • Beta0.6378
Data delayed at least 20 minutes, as of Apr 30 2024 15:11 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nextgen Biomed Ltd is an Israel-based research and development company. Its main activity is to own EyePen product. The Company's product is dedicated to people with diabetes and consists of an injection module which allows to monitor the doses and time of insulin intake. The EyePen mobile app keeps diabetes management systematic by monitoring behavior and provides alerts for human errors such as forgetting a pen, double insulin injections, or skipping injections.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-9.00m
  • Incorporated1990
  • Employees187.00
  • Location
    Nextgen Biomed LtdOppenheimer 7REHOVOT 7670107IsraelISR
  • Phone+972 33742282
  • Fax+972 98849441
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nextgen Biomed Ltd0.00-9.00m8.23m187.00--0.7161-----2.70-2.700.001.420.00-------51.61-32.00-54.98-35.24------------0.1054-------236.16------
Erech Finance Cahalacha Ltd282.00k-25.29m8.43m18.00--1.95--29.89-9.97-9.970.11121.710.0061--0.019---53.84-15.68-132.10-31.24-659.2266.49-8,841.49-133.65---11.040.7966---97.35-50.83-1.01------
Human Xtensions Ltd4.95m-36.64m8.91m50.00--0.3413--1.80-1.37-1.370.1850.97570.09220.46342.2199,000.00-68.25-49.34-77.27-55.6951.6649.34-740.10-485.434.75--0.0608--56.00--17.84---19.95--
Sonovia Ltd0.00-27.00m10.99m44.00--0.3367-----1.67-1.500.001.980.00----0.00-55.93---62.66-------------13.620.0054-------187.75--77.26--
BioLight Life Sciences Ltd118.00k-26.02m20.76m4.00--0.6972--175.93-5.60-5.600.02556.390.0026--0.290329,500.00-60.77-20.22-65.01-21.13-----23,294.07-12,746.09---0.63260.003--87.30-49.76-231.59--92.16--
Elbit Medical Technologies Ltd1.29m-65.97m20.85m232.00--0.7794--16.16-0.7351-0.73510.01470.2950.0211--38.67---108.0237.04-110.4338.19-----5,113.2241.14---0.0110.00--314.29-55.19-248.15------
Erika B-Cure Laser Ltd29.88m-19.22m29.27m----1.23--0.9795-0.185-0.1850.28760.22780.51840.39454.08---33.34---49.63--76.9587.63-64.32-14.480.8936--0.1726---40.62-3.4040.97---19.27--
Allmed Solutions Ltd0.001.42m31.14m19.0017.830.65816.40--0.01820.01820.000.49240.00----0.002.431.432.681.59--50.43--15.58----0.0154------111.71---10.48--
Endymed Ltd84.46m2.05m40.53m46.0019.300.715810.940.480.15260.15266.204.111.132.4618.631,835,987.002.7510.383.3813.3251.2051.922.438.913.02--0.0771--6.774.30-34.94-22.83-15.24--
Data as of Apr 30 2024. Currency figures normalised to Nextgen Biomed Ltd's reporting currency: Israeli Shekel ILS
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.